| General Information | |
|---|---|
| ZINC ID | ZINC000045255880 |
| Molecular Weight (Da) | 411 |
| SMILES | Cc1c(-c2nc[nH]c2C(C)C)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C22Cl2N4 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 116.029 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| LogP | 6.552 |
| Activity (Ki) in nM | 30.903 |
| Polar Surface Area (PSA) | 46.5 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.998 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.18 |
| Ilogp | 3.56 |
| Xlogp3 | 6.17 |
| Wlogp | 6.67 |
| Mlogp | 4.25 |
| Silicos-it log p | 6.37 |
| Consensus log p | 5.4 |
| Esol log s | -6.59 |
| Esol solubility (mg/ml) | 0.000105 |
| Esol solubility (mol/l) | 0.00000025 |
| Esol class | Poorly sol |
| Ali log s | -6.93 |
| Ali solubility (mg/ml) | 0.0000483 |
| Ali solubility (mol/l) | 0.00000011 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.15 |
| Silicos-it solubility (mg/ml) | 0.00000028 |
| Silicos-it solubility (mol/l) | 7.03E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.43 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.39 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.518 |
| Logd | 5.063 |
| Logp | 5.844 |
| F (20%) | 0.003 |
| F (30%) | 0.025 |
| Mdck | - |
| Ppb | 99.09% |
| Vdss | 2.42 |
| Fu | 1.78% |
| Cyp1a2-inh | 0.575 |
| Cyp1a2-sub | 0.432 |
| Cyp2c19-inh | 0.953 |
| Cyp2c19-sub | 0.219 |
| Cl | 6.756 |
| T12 | 0.084 |
| H-ht | 0.171 |
| Dili | 0.979 |
| Roa | 0.46 |
| Fdamdd | 0.635 |
| Skinsen | 0.037 |
| Ec | 0.003 |
| Ei | 0.042 |
| Respiratory | 0.133 |
| Bcf | 3.695 |
| Igc50 | 5.098 |
| Lc50 | 6.968 |
| Lc50dm | 6.008 |
| Nr-ar | 0.035 |
| Nr-ar-lbd | 0.007 |
| Nr-ahr | 0.853 |
| Nr-aromatase | 0.977 |
| Nr-er | 0.866 |
| Nr-er-lbd | 0.625 |
| Nr-ppar-gamma | 0.017 |
| Sr-are | 0.921 |
| Sr-atad5 | 0.552 |
| Sr-hse | 0.744 |
| Sr-mmp | 0.957 |
| Sr-p53 | 0.958 |
| Vol | 402.887 |
| Dense | 1.018 |
| Flex | 0.182 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.408 |
| Synth | 2.63 |
| Fsp3 | 0.182 |
| Mce-18 | 23 |
| Natural product-likeness | -1.111 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |